stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Syngene International Limited

India · NSE: SYNGENE.NS · Market cap: · P/E: · P/S:

Syngene runs laboratories and factories that test, develop, and make medicines for other drug and healthcare companies.

Syngene is a contract research and manufacturing company. Drug companies pay it to do the slow, expensive science they don't want to do themselves: running lab experiments, testing whether a molecule is safe, developing a manufacturing process, and then actually producing the finished medicine at scale. Think of it as an outsourced engine room for the pharmaceutical industry — the client keeps the branding and the blockbuster drug, while Syngene supplies the scientists, the lab benches, and the factory floor.

The business started in 1993 as a research arm attached to an Indian biotech firm, then became independent and grew into a full-service partner. Today its biggest customer is Bristol Myers Squibb, which signed a long-term arrangement that gives Syngene predictable, recurring work rather than one-off projects. That kind of sticky relationship is the heart of the model: once a drug company hands over a program, switching mid-stream is painful, so customers tend to stay. Syngene's real edge is cost and talent. India offers a deep pool of chemists and biologists at a fraction of Western salaries, so global drugmakers can cut research budgets without cutting science. The company does discovery work, safety testing, clinical trial support, and manufacturing of small molecules and biologics — a broad menu that lets it grow with a customer from a single experiment to commercial production.


The risks are honest ones. A big chunk of revenue leans on a handful of large clients, so losing one hurts, and demand tracks whatever the global pharma industry is spending on research. It has also poured money into new labs and manufacturing capacity, which weighs on near-term profits while it waits for those investments to fill up. Still, Syngene sits in a growing niche — the outsourcing of drug discovery and manufacturing — where Western pharma keeps sending more work to specialized partners.

Saved answer · last researched 16 Nov 2026